Cách đây vài ngày người Nga cũng đã tuyên bố vắc xin Sputnik V của họ đạt hiệu quả 92% tuy nhiên làm thế nào có kết quả đó thì họ không công bố (quy trình thử). Báo chí phương Tây không đưa tin nhiều, nếu có thì khá là mỉa mai:
Svetlana Zavidova, a Moscow-based lawyer who heads Russia’s Association of Clinical Trials Organizations and closely follows COVID-19 vaccine R&D in the country. “I’m afraid they looked at the results of Pfizer and added 2%.”
Cho nên, chưa biết ai thắng trong cuộc chiến vắc xin này thì cứ... củ từ.Pfizer and BioNTech and many other companies have made their trial protocols public, but Gamaleya has not. Zavidova notes that she learned more about the details of Gamaleya’s study on a clinical trials website maintained by NIH than she did on a similar registry in Russia, which has “only the name of this protocol without any details.”
In the press release, Alexander Gintsburg, the head of the Gamaleya, promises “mass vaccination in Russia against COVID-19 in the coming weeks.” If the Gamaleya vaccine does become widely available, will Zavidova take it, given that the spread of COVID-19 has rapidly accelerated in Russia? “No,” she says. “I will wait a little bit more.”